Faeth Therapeutics
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
701 Tillery St Ste 12, Austin, Texas, 78...Website
www.faeththerapeutics.comRevenue
-Stock Symbol
FTHIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
1
About Faeth Therapeutics
Faeth Therapeutics is a clinical-stage biotechnology company developing metabolism-based cancer therapies. Using AI-driven computational biology, precision nutrition, and targeted therapeutics, the company identifies metabolic vulnerabilities in tumors to improve cancer treatment outcomes and advance innovative oncology programs.Explore more
Faeth Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Faeth Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Faeth Therapeutics has new funding data
Faeth Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Faeth Therapeutics launches new products
Earning: See what the market has to say on Faeth Therapeutics recently announced quarterly report
Check out if Faeth Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Faeth Therapeutics
Click to see if Faeth Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Faeth Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Faeth Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Faeth Therapeutics
Compare insights from companies similar to Faeth Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Faeth Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Faeth Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Faeth Therapeutics.
Faeth Therapeutics financials insights
Gather financial insights about Faeth Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Angel/Seed
$20M
Series A
$47M
2025
Other Financing Round
$25M
Faeth Therapeutics Tech Stack
A closer look at the technologies used by Faeth Therapeutics
Most Recent Scoops
Person-Based
Open Position
Open Position
Open Position
Open Position
Faeth Therapeutics News & Media
Faeth Therapeutics holder cuts stake to 2.4% | FTH SEC Filing - Form SCHEDULE 13G/A
Caligan Partners now reports 629,467 Faeth Therapeutics shares, or 2.4% of the company, after preferred stock conversion and Nasdaq listing under symbol FTH.Sensei Biotherapeutics: Faeth deal, $200M placement | SNSE Stock News
Funding aims to carry PIKTOR through Phase 2 endometrial data and a Phase 1b breast cancer trial by 2026, after Sensei acquires Faeth and secures $200M.ESMO 2025: Faeth Therapeutics' Phase 2 DICE Trial Shows 34% Reduction in ... - FinancialContent
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus ChemotherapyFaeth Therapeutics Shows Preclinical Proof-of-Concept for Drug-Diet Combination to Treat Cancer, in Peer-Reviewed Publication
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, a clinical-stage biotechnology company integrating precision nutrition with combination therapies to address cancer metabolism, today announced publication of a preclinical proof-of-concept study supporting its rationale for targeting cancer metabolism through multi-node inhibition, including both therapeutics and an insulin-suppressing diet. The findings, published today in the peer-reviewed British Journal of Cancer, show that the three-pron
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Faeth Therapeutics
Sign Up For FreeTo access detailed company insights
Faeth Therapeutics is a clinical-stage biotechnology company developing metabolism-based cancer therapies. Using AI-driven computational biology, precision nutrition, and targeted therapeutics, the company identifies metabolic vulnerabilities in tumors to improve cancer treatment outcomes and advance innovative oncology programs.... Read More
